ANTI-SYNTHETASE SYNDROME
Clinical trials for ANTI-SYNTHETASE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ANTI-SYNTHETASE SYNDROME trials appear
Sign up with your email to follow new studies for ANTI-SYNTHETASE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Matched conditions: ANTI-SYNTHETASE SYNDROME
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: ANTI-SYNTHETASE SYNDROME
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Matched conditions: ANTI-SYNTHETASE SYNDROME
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy trial aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…
Matched conditions: ANTI-SYNTHETASE SYNDROME
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Patients take the lead: rare myositis study puts your voice first
Knowledge-focused Recruiting nowThis study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are …
Matched conditions: ANTI-SYNTHETASE SYNDROME
Sponsor: Myositis International Health & Research Collaborative Alliance Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC